Methods and compositions for inhibiting, destroying, and/or inactivating viruses
The present disclosure provides compositions, methods, and processes for the inhibiting, destroying, and/or inactivating viral contaminants in a biological source material, or treatment of viral infections. The disclosed compositions include one or more quaternary ammonium compounds. One exemplary method includes contacting the biological source material with a solution containing one or more quaternary ammonium salts.
1 . A pharmaceutical composition for the treatment of viral infections comprising a quaternary ammonium salt compound.
2 . The composition of claim 1 , wherein the composition further comprises:
a pharmaceutically acceptable carrier.
3 . The composition of claim 1 , wherein the quaternary ammonium salt compound is chosen from at least one of the following:
monoalkyltrimethyl ammonium salts;
monoalkyldimethylbenzyl ammonium salts;
dialkyldimethyl ammonium salts;
heterocyclic ammonium salts;
pyridinium quaternary salts;
substituted pyridinium quaternary salts; and
bisquaternary ammonium salts.
4 . The composition of claim 3 , wherein the heterocyclic ammonium salt includes an alkyl chain C 8 -C 18 and other alkyl groups bridged to form an aromatic ring.
5 . The composition of claim 1 , wherein the quaternary ammonium salt compound is chosen from at least one of the following: cetyltrimethylammonium bromide (CTAB), benzalkonium chloride, pyridine in cetylpyridinium chloride, lapirium chloride, 4-aminoquinaldinium derivatives, dequalinium chloride, and hedquinium chloride.
6 . A method of treating a host organism for a viral infection comprising administering to the host an effective amount of a composition comprising an quaternary ammonium salt compound.
7 . The method of claim 6 , wherein the composition further comprises:
a pharmaceutically acceptable carrier.
8 . The method of claim 6 , wherein the quaternary ammonium salt compound is chosen from at least one of the following:
monoalkyltrimethyl ammonium salts;
monoalkyldimethylbenzyl ammonium salts;
dialkyldimethyl ammonium salts;
heterocyclic ammonium salts;
pyridinium quaternary salts;
substituted pyridinium quaternary salts; and
bisquaternary ammonium salts.
9 . The method of claim 8 , wherein the heterocyclic ammonium salt includes an alkyl chain C 8 -C 18 and other alkyl groups bridged to form an aromatic ring.
10 . The method of claim 6 , wherein the quaternary ammonium salt compound is chosen from at least one of the following: cetyltrimethylammonium bromide (CTAB), benzalkonium chloride, pyridine in cetylpyridinium chloride, lapirium chloride, 4-aminoquinaldinium derivatives, dequalinium chloride, and hedquinium chloride.
11 . A method of inhibiting, destroying, and/or inactivating viral contaminants in a biological source material comprising contacting the biological host material with a quaternary ammonium salt compound.
12 . The method of claim 11 , wherein the composition further comprises:
a pharmaceutically acceptable carrier.
13 . The method of claim 11 , wherein the quaternary ammonium salt compound is chosen from at least one of the following:
monoalkyltrimethyl ammonium salts;
monoalkyldimethylbenzyl ammonium salts;
dialkyldimethyl ammonium salts;
heterocyclic ammonium salts;
pyridinium quaternary salts;
substituted pyridinium quaternary salts; and
bisquaternary ammonium salts.
14 . The method of claim 13 , wherein the heterocyclic ammonium salt includes an alkyl chain C 8 -C 18 and other alkyl groups bridged to form an aromatic ring.
15 . The method of claim 1 1 , wherein the quaternary ammonium salt compound is chosen from at least one of the following: cetyltrimethylammonium bromide (CTAB), benzalkonium chloride, pyridine in cetylpyridinium chloride, lapirium chloride, 4-aminoquinaldinium derivatives, dequalinium chloride, and hedquinium chloride.